Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

D’Avolio, Antonio; Pensi, Debora; Baietto, Lorena; Pacini, Giovanni; Perri, Giovanni Di; Rosa, Francesco Giuseppe De

doi:10.1007/s40265-016-0610-3

Cited by 33 publications

(31 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, FM (83 mg/L) combined with DAP (20.6 mg/L) and DAP monotherapy (47.1 mg/L) reduced the population of four VRE isolates to zero without re-growth at 24h. Previous reports demonstrated FM combined with DAP had synergistic effects as well [17,36]. Therefore, the combination of FM and DAP for patients with VRE infections, especially for patients with renal impairment, is of great signi cance for further clinical trials.…”

Section: Discussionmentioning

confidence: 99%

In Vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

OBJECTIVESThe emergence of vancomycin resistant enterococci (VRE) is shortening the choices for clinical anti-infective therapy. The aim of this study was to investigate the mechanism of vancomycin resistance and evaluate the effect of fosfomycin (FM), rifampin (RIF), vancomycin (VAN), linezolid (LNZ), daptomycin (DAP) alone or in combination against VRE.METHODSEight VRE isolates were collected. A total of 18 antibiotics susceptibility tests were further done for VRE. Whole genome sequencing and bioinformatics analysis were performed. The effect of FM, RIF, VNA, LNZ, DAP alone or in combination was determined using anti-biofilm testing and the time-kill assay.RESULTSAll isolates were susceptible to LNZ and DPA. The high-level resistance determinant of VAN in these strains was due to VanA-type cassette. MLST revealed two different STs for vancomycin-resistant Enterococcus faecium (VREm) and four different STs for vancomycin-resistant E. faecalis (VREs). Virulence genes in VREs were more than VREm, especially for 4942 isolated from blood. Gene acm and uppS were only identified in VREm, while virulence genes related to cytolysin were only found in E. faecalis. Further in vitro anti-biofilm testing and time-kill assay found FM (83 mg/L) combined with DAP (20.6 mg/L) and DAP monotherapy (47.1 mg/L) showed bactericidal effect against 8 tested VRE strains at 24h. CONCLUSIONSThe high-level resistance determinant of VAN in these strains was due to VanA-type cassette. FM combined with DAP might be greater potential therapeutic option against VRE.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci

Jiang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Las concentraciones plasmáticas de CPK deben controlarse semanalmente o, con mayor frecuencia, en pacientes con mialgias, miopatías o insuficiencia renal concomitante, o cuando se administran conjuntamente con fármacos asociados con el incremento de CPK 13 .…”

Section: Discussionunclassified

Experiencia con el uso de daptomicina en un hospital pediátrico de alta complejidad

Rosanova

Sberna

Sarkis

et al. 2020

Rev. chil. infectol.

View full text Add to dashboard Cite

Background: Vancomycin has been considered the treatment of choice especially for methicillin-resistant Staphylococcus aureus (MRSA) infections; but its poor tissue penetration, renal toxicity, and requiring of dosages monitoring, raises the need for new treatment alternatives such as daptomycin. Aims: To analyze the safety and effectiveness of daptomycin in children. Methods: Children with microbiologically documented infections treated with daptomycin were retrospectively included. Results: The most frequent infections were endocarditis in 9 (32%), sepsis in 4 (14%), bacteremia in 7 (associated with catheter in 3) (25%), osteomyelitis in 3 (10%), peritonitis associated with dialysis in 3 (10%) and suppurative thrombophlebitis in 2 patients (p) (7%). Methicillin-resistant Staphylococcus aureus was the most common pathogen in 18 patients (64%). The indications for daptomycin were due to the failure of conventional treatment in 17 (61%), and the toxicity or intolerance to vancomycin in 11 patients (39%). The average duration of treatment was 19 days (95% ICR 7-42 days). Four patients (14%) completed outpatient treatment, 22 patients had a favorable response (79%). Adverse events were reported in 3 patients (2 creatinine-phosfo-kinase increase) and in one severe skin rash. Conclusions: Daptomycin demonstrated a favorable efficacy and safety in this pediatric population.

show abstract

“…The bactericidal activities of FM, VAN and DAP, alone or in combination, against the five LZR-Efa isolates and ATCC 29212 were investigated using the time–kill method [ 10 ]. The following concentrations were used: FM 83 mg/L [ 11 ]; VAN 13.3 and 6 mg/L [ 12 ]; DAP, 20.6, 31.1 and 47.1 mg/L [ 13 ]; FM 83 mg/L + VAN 13.3 mg/L; FM 83 mg/L + VAN 6 mg/L; and FM 83 mg/L + DAP 20.6 mg/L. The media were supplemented with 25 mg/L G6P for testing of FM.…”

Section: Methodsmentioning

confidence: 99%

In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus faecalis

Zhang

Tong

et al. 2020

Infect Dis Ther

View full text Add to dashboard Cite

Introduction: Enterococcus faecalis is a significant cause of nosocomial infections and is difficult to treat because of intrinsic and acquired resistance to many antibiotics. In addition, the emergence of linezolid-resistant E. faecalis (LZR-Efa) is reducing the choices available for antiinfective therapy. The aim of this study was to examine the in vitro antibacterial effects of fosfomycin (FM), vancomycin (VAN) and daptomycin (DAP), alone and in combination, against LZR-Efa. Methods: Five LZR-Efa strains and E. faecalis ATCC 29212 were studied. The antibacterial effects of FM, and of FM, VAN and DAP, were assessed using the time-kill assay. Biofilm formation and elimination were evaluated by crystal violet staining. Results: When used at concentrations greater than 0.5 9 MIC, FM did not produce dose-dependent effects against LZR-Efa isolates. The use of DAP (47.1 mg/L) alone, and FM (83 mg/L) combined with DAP (20.6 mg/L), produced a persistent inhibitory effect against both planktonic LZR-Efa isolates and those forming biofilms. In addition, FM and VAN combined with glucose-6-phosphate produced visible eradication effects against biofilms grown for 24 h, while DAP alone or combined with FM resulted in the best eradication activity against biofilms grown for 72 h prior to exposure. Conclusion: The use of FM combined with DAP provided the best potential therapeutic option for treating LZR-Efa infections out of those tested. In addition, the optimum treatment for biofilm elimination depended on the stage of biofilm formation.

show abstract

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

Cited by 33 publications

References 109 publications

In Vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci

In Vitro Antimicrobial Activity of Fosfomycin, Rifampin, Vancomycin, Daptomycin Alone and in Combination Against Vancomycin-Resistant Enterococci

Experiencia con el uso de daptomicina en un hospital pediátrico de alta complejidad

In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus faecalis

Contact Info

Product

Resources

About